Navigation Links
Cryoablation -- A new treatment option for some kidney tumor patients

Mayo Clinic researchers report that freezing kidney tumors through percutaneous cryoablation shows promise for patients who are not good candidates for surgery. Their early findings showing short-term success in more than 90 percent of selected patients are published in this month’s issue of Radiology.

The standard treatment for kidney tumors is surgery, providing a high likelihood of a long-term cure. For some patients, surgery is not an option, and Mayo’s urologists and radiologists collaborated to find alternatives for these individuals. If these patients are frail due to age or illness or are not able to have surgery because of other factors, percutaneous cryoablation may be an option.

"This procedure appears to be a good option for some patients," says Thomas Atwell, M.D., Mayo Clinic radiologist and the study’s primary investigator. "It makes their hospital stay and recovery time very short and surgical stress is minimal." He cautions that this procedure is not ideal for everyone, noting that it is an option for only a relatively small subset of patients.

Percutaneous ablation uses needles to penetrate the skin and deliver directly to the tumor either high-intensity, tissue-destroying heat through radiofrequency ablation, or freezing cold through cryoablation. Mayo Clinic’s radiologists are among the most experienced in the world in performing ablation techniques, and have treated nearly 300 kidney tumors either with radiofrequency ablation or cryoablation. Radiofrequency ablation (RFA) burns away the tumor, while cryoablation freezes it.

Mayo Clinic doctors had previous experience with liver tumor cryoablation when they added kidney tumor cryoablation in 2003. Today’s report contains the largest published results for percutaneous cryoablation patients. Mayo researchers report that not only can this technique be an alternative to surgery, but that in some cases, it has benefits over RFA.

Previous experien
'"/>

Source:Mayo Clinic


Page: 1 2 3

Related biology news :

1. Protein discovery could unlock the secret to better TB treatment
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
4. Researchers add new tool to tumor-treatment arsenal
5. Potential treatments for neurofibromatosis
6. Nanoparticles offer new hope for detection and treatment
7. Technique may allow cancer patients to freeze eggs, preserving fertility before starting treatment
8. PET/CT can identify new cancer lesions at early stage, allowing for prompt treatment
9. New understanding of DNA repair may pave way to cancer treatments
10. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
11. Newer imaging techniques may lead to over-treatment

Post Your Comments:
(Date:11/4/2009).... Louis, MO, November 4, 2009 Childhood obesity i...ns. With more than one fourth of advertising on da...nd beverages and continuing questions about the ro...ember/December issue of the Journal of Nutrition ...ing aimed at children might be a large contributor...
(Date:11/4/2009)..., PORTOLA VALLEY, Calif., Oct. 19 ...olecular sensing and imaging devices which shed li...that it has signed exclusive distribution deals fo...nsors. The markets covered include Australia, New...enelux), Suriname, Italy, France, Spain, Portugal,...
(Date:11/4/2009)..., RIDGE, N.Y., Oct. 21 What,s the ...eventing accidental death resulting from prescript...s with good intentions, however, may be unaware th...ting their teens from the ticking timebomb of pres...leader in premium-quality medical supplies, has fo...
Breaking Biology News(10 mins):TV bombards children with commercials for high-fat and high-sugar foods 2TV bombards children with commercials for high-fat and high-sugar foods 3Spectros Signs New International Distribution Deals 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 2MEDNET Launches MedSafe to Prevent Teenage Prescription Drug Abuse 3AMA Medicare Campaign Kicks Off With New TV Ads 59585 1AMA Medicare Campaign Kicks Off With New TV Ads 59585 2AMA Medicare Campaign Kicks Off With New TV Ads 59585 3Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 1Micro Waste Corporation Ordered to Pay Sanitecs Attorney Fees 59583 2ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 1ViroPharma to Release 2009 Third Quarter Financial Results on October 28 2009 59581 2
...of Standards and Technology (NIST) last week issue... and growing field of tissue engineering for medic...al tissue scaffold material that have been measure...es of porosity. , Three-dimensional tissue scaffo...adable materials that are meant to be implanted in...
...nt pieces of the climate change puzzle together is...is a key piece of this puzzle, but the size and sh...opardises the reliability of all current predictio...ct has been launched at the University of Leeds to...te. , Aerosols are small particles suspended in...
...f melanin -- the color pigment in skin and hair --...sed susceptibility to nicotine dependence and toba...rs, according to scientists., "We have found that...to the number of cigarettes smoked daily, levels o... African Americans," said Gary King, professor of ...
Other Biology News:NIST issues first reference material for tissue engineering 2Aerosol: A key piece of the climate change puzzle 2Skin color clue to nicotine dependence 2
(Date:11/5/2009)...FREMONT, Calif., Nov. 5 ...S), a leading developer of state-of-the-art geneti...er Sears, Ph.D. has joined the company,s Scientifi...designing and commercializing novel molecular diag...s, and on the development of computational biology...
(Date:11/5/2009)... LASIK Surgery and vision corre... directory were actively involved at the recently ...2009 Annual Meeting in San Francisco, California. ...MD, Dr. Jonathan Davidorf, MD, Dr. Peter Rapoza, M..., Dr. R. Wayne Bowman, MD, Dr. Edward Manche, MD, ...
(Date:11/4/2009)...HUNTSVILLE, Ala., Nov. 4 DIATHERIX...om ), today presented at the Michigan Security Ne...ce in Dearborn, Mich. Dennis Grimaud, Chairman and...he impact of the company,s advanced molecular diag...nse, infectious disease diagnosis and military eff...
(Date:11/4/2009)...SAN CARLOS, Calif., Nov. 4 /PRNewswire-FirstCall/ ...rted its financial results for the third quarter e...uarter ended September 30, 2009 improved to $31.0 ...oss of $37.0 million or $0.40 per share in the thi...ake improvements to its operating efficiencies as ...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...ociates, Inc.,administrator for the HealthShares(T...the HealthShares(TM) Exchange-Traded Funds, today ... on Tuesday February 26, 2008, KV,Pharmaceutical C...ls, Inc.,(NYSE: BDY ) in the HealthShares(TM) Der...quired by Nycomed US Inc., a subsidiary of Nycomed...
...ration,(Nasdaq: BPUR ) today announced its financ...uary 31, 2008. For the quarter, the company report... share, compared with a net loss,of $6.9 million, ...eriod in,2007. Class A common shares outstanding o...,543,025, respectively., Revenues, Total revenue...
...ntered into an Agreement Under, Which Genmab Will ...ted in Brooklyn Park, Minnesot...ifornia, February 21, Genmab A/S (OMX: GEN) and PD... that they have entered into an agreement,under wh...ing facility,located in Brooklyn Park, Minnesota, ...
Other Biology Technology:Biopure Announces 2008 First Quarter Financial Results 2Biopure Announces 2008 First Quarter Financial Results 3Biopure Announces 2008 First Quarter Financial Results 4Biopure Announces 2008 First Quarter Financial Results 5Biopure Announces 2008 First Quarter Financial Results 6Biopure Announces 2008 First Quarter Financial Results 7Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 2Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 3Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 4Genmab and PDL BioPharma Sign Purchase Agreement for Antibody Manufacturing Facility 5
Anti-Mouse VEGF-C Antibody, Unconjugated from Raybiotech, Inc.
Annexin V Binding Buffer from BD Biosciences Pharmingen
Mouse Anti-Cytokeratin 8 + 18 + 19 Monoclonal Antibody, Unconjugated, Clone 2A4 from Abcam
Tube-O-DIALYZER Floats, Floats, Small from CHEMICON
Biology Products: